Top Stories
Business & Policy
- Hims
- Grail
- Zealand
- Regulatory pathway for “bespoke” gene therapies
- Novartis malaria drug
Research
1. Hims launches lab testing for preventive care
- Hims & Hers is launching lab testing for health markers in areas like heart health and metabolism as blood testing grows more popular with consumers who want to better understand their health. The idea is …
2. Grail sees Q3 sales jump, eyes Q1 for FDA Galleri PMA submission
- Grail saw a sharp rise in third-quarter sales as it outlined a firmer FDA submission date for its Galleri cancer blood test.
36. Zealand hits pause on dual GLP-1/GLP-2 asset as CMO cites ‘increasingly crowded’ metabolic development scene
biotech & business healthtech & business
Article ID: c5e31818d605
Source: Fierce Biotech
Published: Nov 13, 2025 9:40am
URL: https://www.fiercebiotech.com/biotech/zealand-hits-pause-dual-glp-1glp-2-asset-cmo-cites-increasingly-crowded-metabolic
Summary: Zealand is pausing development on its dual GLP-1/GLP-2 agonist, known as dapiglutide, as it strives to focus its time and money on “programs with the greatest potential for clinical differentiation and long-term value creation,” the company said in an earnings announcement.
57. STAT+: Makary, Prasad outline pathway for bespoke gene therapy
biotech & business healthtech & business basic biomedical research breakthroughs
Article ID: 8786ce37f8e5
Source: STAT News
Published: Thu, 13 Nov 2025 14:39:56 +0000
URL: https://www.statnews.com/2025/11/13/biotech-news-fda-outlines-gene-editing-pathway/?utm_campaign=rss
Summary: And other biotech news, brought to you by The Readout
38. Novartis’ resistance-busting malaria drug GanLum hits phase 3 goal
biotech & business healthtech & business basic biomedical research breakthroughs
Article ID: 5428e1b9630f
Source: Fierce Biotech
Published: Nov 13, 2025 3:58am
URL: https://www.fiercebiotech.com/biotech/novartis-resistance-busting-malaria-drug-ganlum-hits-phase-3-goal
Summary: A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites.
2. AISAP Launches FDA-Cleared Platform in Ghana to Solve Cardiologist Shortage
Article ID: 4120a483df1f
Source: HIT Consultant
Published: Thu, 13 Nov 2025 13:33:00 +0000
Summary: What You Should Know: – AISAP, an AI Point-of-Care Diagnostics company, announced a landmark field initiative in Ghana to deploy its FDA-cleared AI-powered cardiac diagnosis platform. This program directly addresses the profound challenge of healthcare access in Ghana, a country of approximately 35 million people served by fewer than 30 cardiologists. – The initiative, in … Read More
28. Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
biotech & business healthtech & business
Article ID: a39a72a51a13
Source: All News
Published: Thu, 13 Nov 2025 12:39:28 GMT
URL: https://www.biospace.com/business/recently-launched-third-arc-turns-to-china-for-cancer-t-cell-engagers
Summary: The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to disclose priority indications.
29. 21 Companies Miss Massachusetts Hiring Targets, Affecting Hundreds of Jobs
biotech & business healthtech & business
Article ID: bfc7171f6b5d
Source: All News
Published: Thu, 13 Nov 2025 05:00:00 GMT
URL: https://www.biospace.com/job-trends/21-companies-miss-massachusetts-hiring-targets-affecting-hundreds-of-jobs
Summary: Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 combined jobs hit just 13% of that target in 2024. Ten awardees had reported layoffs last year, including Charles River Laboratories and Moderna.
35. Day One pens $285M deal for Mersana and its clinical-stage B7-H4 ADC
biotech & business healthtech & business
Article ID: de35c4723e9b
Source: Fierce Biotech
Published: Nov 13, 2025 9:41am
URL: https://www.fiercebiotech.com/biotech/day-one-pens-285m-deal-mersana-and-its-clinical-stage-b7-h4-adc
Summary: Mersana Therapeutics’ decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid off.
Research
49. GlioSurv: interpretable transformer for multimodal, individualized survival prediction in diffuse glioma
applied AI in medicine digital health
Article ID: 040f24e3a6fd
Source: npj Digital Medicine
Published: 2025-11-14
URL: https://www.nature.com/articles/s41746-025-02018-x
Summary: npj Digital Medicine, Published online: 14 November 2025; doi:10.1038/s41746-025-02018-xGlioSurv: interpretable transformer for multimodal, individualized survival prediction in diffuse glioma
50. From retina to brain: how deep learning closes the gap in silent stroke screening
applied AI in medicine digital health frontier AI/ ML & bio research
Article ID: 7db9c8d4c878
Source: npj Digital Medicine
Published: 2025-11-13
URL: https://www.nature.com/articles/s41746-025-02021-2
Summary: npj Digital Medicine, Published online: 13 November 2025; doi:10.1038/s41746-025-02021-2Silent brain infarctions (SBIs), affecting 20% of adults and increasing stroke risk, evade routine MRI screening. While retinal scans offer a “window to the brain,” prior AI failed to simultaneously detect SBIs and predict strokes. DeepRETStroke overcomes this by analysing eye scans. Trained on ~900,000 images, it uses deep learning combining self-supervised pattern recognition from unlabeled images, semi-supervised SBI detection with limited MRI, and knowledge transfer refinement, transforming eye exams into affordable stroke screenings.
51. Diurnal variation of wearable device-based heart rate variability in the Chronic Renal Insufficiency Cohort study
digital health
Article ID: ca711a2d405b
Source: npj Digital Medicine
Published: 2025-11-13
URL: https://www.nature.com/articles/s41746-025-02010-5
Summary: npj Digital Medicine, Published online: 13 November 2025; doi:10.1038/s41746-025-02010-5Diurnal variation of wearable device-based heart rate variability in the Chronic Renal Insufficiency Cohort study
43. Pig-organ transplants are often rejected — researchers find a way to stop it
basic biomedical research breakthroughs
Article ID: 3f00146fd7e6
Source: Nature
Published: 2025-11-13
URL: https://www.nature.com/articles/d41586-025-03750-w
Summary: Nature, Published online: 13 November 2025; doi:10.1038/d41586-025-03750-w The successful treatment in a brain-dead man could be used in living people, to prevent the immune system attacking donor organs.
47. Microbial signals in primary and metastatic brain tumors
basic biomedical research breakthroughs
Article ID: 74109e921f59
Source: Nature Medicine
Published: 2025-11-14
URL: https://www.nature.com/articles/s41591-025-03957-4
Summary: Nature Medicine, Published online: 14 November 2025; doi:10.1038/s41591-025-03957-4 A combination of high-resolution spatial imaging, spatial proteomics and transcriptional data reveals sparse and heterogeneous bacterial signals in gliomas and brain metastases.
52. Changes in emergency and primary care use after adding virtual physicians to HealthLink BC’s 8-1-1 program
digital health
Article ID: c4d88635b0c1
Source: npj Digital Medicine
Published: 2025-11-13
URL: https://www.nature.com/articles/s41746-025-02060-9
Summary: npj Digital Medicine, Published online: 13 November 2025; doi:10.1038/s41746-025-02060-9Changes in emergency and primary care use after adding virtual physicians to HealthLink BC’s 8-1-1 program
53. AI-driven prediction of progression to oral squamous cell carcinoma using a multiresolution pathology model
applied AI in medicine
Article ID: 14f0f2d37055
Source: npj Digital Medicine
Published: 2025-11-13
URL: https://www.nature.com/articles/s41746-025-02014-1
Summary: npj Digital Medicine, Published online: 13 November 2025; doi:10.1038/s41746-025-02014-1AI-driven prediction of progression to oral squamous cell carcinoma using a multiresolution pathology model
4. Assessing the Case Against Direct-to-Consumer Drug Advertisements
public policy
Article ID: afe44a4e503c
Source: JAMA Health Forum New Online
Published: Fri, 14 Nov 2025 00:00:00 GMT
URL: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2841229
Summary: This Viewpoint assesses concerns regarding direct-to-consumer advertising of prescription drugs.
3. Internet Searches for Lorazepam Following the Release of The White Lotus
digital health
Article ID: 06c6d3438fd4
Source: JAMA Health Forum New Online
Published: Fri, 14 Nov 2025 00:00:00 GMT
URL: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2841233
Summary: This cross-sectional study examines whether there was an uptick in online searches about lorazepam after the release of the third season of The White Lotus.